Analyst
Guggenheim Securities
Equibles does not estimate personal net worth.
Vamil Divan is recorded as Analyst at Guggenheim Securities. Vamil Divan has spoken on 3 earnings calls across 2 companies, most recently for Travere Therapeutics, Inc. on August 4, 2026. Those appearances were for AbbVie Inc. (ABBV) and Travere Therapeutics, Inc. (TVTX). The companies whose calls Vamil Divan spoke on are classified in the Healthcare sector.
“So, I guess my question is on the FSGS launch and following up on some of what Peter said regarding sort of the shape of the curve from here and how we should think about it obviously starting at a much higher point than we were expecting i know you mentioned some summer seasonality um but if you can just give us a…”
“So maybe one I do have actually is still on the Botox topic, and then one other one. On Botox, we were sort of surprised to see that one selected for the Medicare price reductions in 2028.”
“I was curious, given the recent performance the company has had with the erosion since the introduction of biosimilars, can you now provide a better sense around the company's expectations on Humira's longer-term tail revenues in both the U.S. and ex-U.S. markets?”
Guggenheim Securities
Analyst
Source not stated
ABBV
Drug Manufacturers - General · Healthcare
